Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
Commentary|Videos|November 22, 2024
Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic Astrocytoma
Author(s)Rimas V. Lukas, MD
Rimas V. Lukas, MD, discusses the efficacy of eflornithine plus lomustine in recurrent IDH-mutant anaplastic astrocytoma per 2021 WHO diagnostic criteria.
Advertisement
Rimas V. Lukas, MD, neuro-oncologist, associate professor, Neurology, Northwestern University Feinberg School of Medicine, discusses key efficacy data and implications from the phase 3 STELLAR trial (NCT02796261) evaluating eflornithine plus lomustine vs lomustine in patients with recurrent IDH-mutant anaplastic astrocytoma per 2021 World Health Organization diagnostic criteria.
Advertisement
Related to this article
Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
SurVaxM missed the SURVIVE trial OS end point in newly diagnosed glioblastoma, whereas a subgroup of patients 65 or younger had significantly improved OS.
Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.
Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
2
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
3
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
4
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
5